

Vaginal estrogen use and chronic disease risk in the Nurses' Health Study

Shilpa N. Bhupathiraju, PhD,^{1,2} Francine Grodstein, ScD,^{1,3} Meir J. Stampfer, MD, DrPH,^{1,2,3,4} Walter C. Willett, MD, DrPH,^{1,2,3} Carolyn J. Crandall, MD, MS,⁵ Jan L. Shifren, MD,⁶ and JoAnn E. Manson, MD, DrPH^{1,3,4}

Abstract

Objective: To examine the associations between vaginal estrogen use and multiple health outcomes including cardiovascular disease (total myocardial infarction, stroke, and pulmonary embolism/deep vein thrombosis), cancer (total invasive, breast, endometrial, ovarian, and colorectal cancer), and hip fracture.

Methods: We included postmenopausal women from the Nurses' Health Study (1982-2012) who were not current users of systemic hormone therapy at the start of the study or during follow-up. Vaginal estrogen use was self-reported on the biennial questionnaires. Information on incident health outcomes were self-reported and confirmed by medical records. We used Cox proportional hazards regression to model the multivariable adjusted hazard ratios and the 95% confidence intervals for vaginal estrogen use and multiple health outcomes.

Results: Over 18 years of follow-up, after adjusting for covariates, risks for cardiovascular disease, cancer, and hip fracture were not different between users and nonusers of vaginal estrogen. No statistically significant increase in risk of any health outcome was observed with vaginal estrogen use. In sensitivity analyses, when we examined associations by hysterectomy status, the stratified results were generally similar to those for the total cohort.

Conclusions: Vaginal estrogen use was not associated with a higher risk of cardiovascular disease or cancer. Our findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause.

Key Words: Cancer – Cardiovascular disease – Chronic disease – Hormone therapy – Vaginal estradiol – Vaginal estrogen.

Genitourinary syndrome of menopause (GSM) is a chronic condition that is associated with a decrease in exposure of the urogenital tissues to estrogen.¹ Vulvovaginal atrophy and atrophic vaginitis are components of GSM, which affects a substantial proportion of postmenopausal women with prevalence estimates ranging from as low as 25% to as high as 70%.²⁻⁴ GSM encompasses a constellation of signs and symptoms including genital symptoms of dryness, burning, and irritation; sexual symptoms of

lack of lubrication, discomfort or dyspareunia; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections.⁵ Unlike vasomotor symptoms, symptoms of GSM do not resolve over time, are chronic, and can become progressively worse without treatment.⁶ They can significantly impair quality of life^{7,8} and despite their high prevalence, they remain largely underdiagnosed.⁶

Low-dose vaginal estrogen therapy is the preferred and most effective treatment for GSM and is recommended by The North American Menopause Society, the American College of Obstetricians and Gynecologists, the Endocrine Society, and other professional societies.^{6,9-11} Although non-hormonal options are available, a systematic review of evidence from randomized controlled trials and prospective comparative studies has shown that vaginal estrogen therapy was superior to nonhormonal therapies in improving symptoms in patients with two or more complaints.¹² A meta-analysis of 58 comparative studies of postmenopausal women with GSM found that vaginal estrogen therapy correlated with better patient reports of symptom relief compared to oral estrogen therapy.¹³ A more recent Cochrane Database Systematic Review found that all commercially available vaginal estrogens effectively relieve symptoms with no difference in efficacy between the various regimens (creams, tablets, rings).¹⁴ Although a recent 12-week multicenter randomized

Received August 23, 2018; revised and accepted November 5, 2018.

From the ¹Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA; ³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; ⁴Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ⁵Department of Medicine, University of California at Los Angeles, Los Angeles, CA; and ⁶Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Funding/support: S.N.B. is supported by a Career Development Grant from the NIH (K01 DK107804). The Nurses' Health Study is supported by grants from the National Institutes of Health UM1 CA186107, P01 CA87969, R01 HL034594, and R01 HL088521.

Financial disclosures/conflicts of interest: None reported.

Address correspondence to: Dr JoAnn E. Manson, MD, DrPH, Chief, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave, 3rd Floor, Boston, MA 02215. E-mail: jmanson@rics.bwh.harvard.edu

clinical trial showed that neither a vaginal tablet nor moisturizer provided additional benefit over a placebo gel in the relief of postmenopausal vulvovaginal symptoms,¹⁵ this was a short-duration trial with several limitations.¹⁶ Despite the availability of strong and generally consistent data to show its effectiveness, low-dose vaginal estrogen therapy remains underutilized owing to perceived risks associated with menopausal hormone therapy.¹⁷ In addition, the FDA-issued black-box warning on the low-dose vaginal estrogen package label discourages clinicians from prescribing the product and women from using prescribed therapy.¹⁸ However, these warnings stem from evidence generated by randomized clinical trials of systemic hormone therapy,¹⁹ which used much higher doses of estrogen. Unlike oral estrogen therapy, vaginal estrogen is not subject to gastrointestinal conversion of estradiol (E2) to estrone and avoids the first-pass liver metabolism associated with increased hepatic synthesis of thrombotic and other factors.^{18,20} Furthermore, the substantial increases in blood hormone levels seen with systemic estrogen treatment are not observed in treatment with the recommended low doses of vaginal estrogen where serum hormone concentrations remain within the postmenopausal range.²¹⁻²⁶

Randomized clinical trial data on the effect of low-dose vaginal estrogen therapy on major chronic disease outcomes such as cardiovascular disease and cancer are lacking. Evidence from population-based cohort studies has been limited with one study reporting no association between vaginal estrogen use and risk of breast cancer and endometrial cancer,²⁷ another reporting a higher risk of endometrial cancer,²⁸ and a few others demonstrating a lower risk of coronary heart disease and stroke.^{27,29,30} Given the overall limited data on risks and benefits associated with long-term use of low-dose vaginal estrogen use among women not using systemic hormone therapy, we aimed to examine the prospective associations between vaginal estrogen use and chronic disease outcomes among postmenopausal women in the Nurses' Health Study.

METHODS

Study population

The Nurses' Health Study (NHS) began in 1976 as a long-term prospective investigation of the health effects of various contraceptive methods in female registered nurses residing in 11 US states. Every 2 years, participants returned a mailed validated questionnaire that obtained detailed and updated information on their lifestyle, behavioral, personal, and reproductive factors, medical history, health status, and a range of other exposures and covariates.³¹⁻³⁴ A response rate of at least 90% has been achieved in most follow-up cycles.

Assessment of vaginal estrogen use

Beginning in 1982, use of vaginal estrogen was ascertained through self-report on the main questionnaire. We did not collect information on dose or specific type of vaginal estrogen regimen (cream, ring, tablet, or suppository). When information regarding vaginal estrogen use was missing, we carried forward information from the previous cycle.

Outcome ascertainment

In order to understand whether the risks and benefits associated with systemic hormone therapy also apply to vaginal estrogen use, we considered the following outcomes in our analyses: cancer outcomes (all cancer types and site-specific cancers including invasive breast, ovarian, endometrial, and colorectal cancer), cardiovascular outcomes (total myocardial infarction [MI], stroke, and pulmonary embolism/deep vein thrombosis), and hip fracture.

To confirm cases of MI, we used the World Health Organization criteria, which include typical symptoms and either elevated enzymes or diagnostic electrocardiographic findings.³⁵ Furthermore, as specified by the European Society of Cardiology and the American College of Cardiology, elevated cardiac specific troponin are diagnostic of MI when accompanied by pain or electrocardiogram changes.³⁶ We confirmed MI deaths if the autopsy report showed evidence of fresh infarction or thrombus or if there were electrocardiogram and enzyme changes characteristic of MI before death by medical records. We did not include sudden cardiac deaths without evidence of MI in our analyses. We classified stroke according to the National Survey of Stroke criteria,³⁷ which require evidence of a neurological deficit with sudden or rapid onset that persisted for more than 24 hours or until death. We excluded cerebrovascular pathology due to infection, trauma, or malignancy, and "silent" strokes discovered only by radiologic imaging. Pulmonary embolism cases were confirmed if a ventilation/perfusion lung scan was read by a radiologist as high probability for pulmonary embolism, or if there was a filling defect on contrast-enhanced computed tomography of the pulmonary vasculature or on catheter-based pulmonary angiography. We included both "idiopathic" (defined by the absence of recent surgery, major trauma, or active malignancy) and "nonidiopathic" cases (associated with recent surgery, trauma, or malignancy) in our analyses.^{38,39} Physician-diagnosed deep vein thrombosis was identified from participants writing in this diagnosis on the biennial questionnaires on a blank line reserved for "other conditions". For the current analysis, we included any report of pulmonary embolism or deep vein thrombosis that was confirmed by medical records or by additional evidence from the participant.

For all cancer types, we considered all pathologically confirmed and probable cases of invasive cancer (except nonmelanoma skin cancer). For breast cancer, we included only confirmed cases with evidence of invasion (including microinvasion) on the pathology report. Cases of carcinoma in situ were not included in our analyses. Cases of ovarian and endometrial cancer were reported on the biennial questionnaires. For all reported cases, we requested medical records pertaining to the diagnosis. For cases in which records were unavailable, we confirmed diagnoses through state cancer registries. For ovarian and endometrial cancer, incident cases were confirmed after review of pathology reports by a gynecologic pathologist.⁴⁰ Incident cases of colorectal cancer were confirmed by a review of medical records by study physicians.

Colorectal cancer and subsites were defined according to the International Classification of Diseases, Ninth Revision.⁴¹

Deaths were identified by reports from next-of-kin or from the US postal service when a questionnaire or newsletter mailed to a participant is returned. Deaths were also identified through a search of the National Death Index. To identify the primary cause of death, attempts were made to contact the next-of-kin to request permission to obtain medical records. Information was also obtained from the National Death Index, from tumor registries, and from death certificates obtained from state vital statistics departments. Deaths were classified according to the International Classification of Diseases, Eighth Revision (ICD-8) as cardiovascular deaths (ICD-8 codes 390-458) or cancer deaths (ICD-8 codes 140-207). Follow-up for deaths was more than 98% complete.^{42,43}

Assessment of covariates

In the biennial follow-up questionnaires, we updated information on age, weight, smoking status, physical activity, aspirin use, history of bilateral oophorectomy, personal history of chronic disease, and mammogram screening in the previous cycle. Height and age at first birth were determined in 1976. Information on race was obtained in 1992 and 2004. Parental history of MI was ascertained in 1976 and in 1984. Family history of cancer was first ascertained in 1976 and again in the years 1982, 1992, 1996, 2004, and 2008. Parity was assessed from 1976 to 1984 and again in 1996. Cumulative duration of systemic hormone therapy use and vaginal estrogen use was calculated for the years that women reported their use. Alcohol intake was measured every 4 years using the food frequency questionnaire.

Statistical analysis

Beginning in 1982 we included women on a rolling basis as they became postmenopausal. For the current analysis, we excluded current (but not past) users of systemic hormone therapy at the time of study enrollment. We also excluded women with previously diagnosed cancer (except nonmelanoma skin cancer). For cardiovascular outcomes, we also excluded participants with self-reported cardiovascular disease. Person-time was calculated from the time a participant entered the analysis to the first diagnosis of an outcome, start of systemic hormone therapy use, loss to follow-up, death, or the cut-off date (June 2012) whichever came first.

For all outcomes, we used time-varying updates of vaginal estrogen use. We used Cox proportional hazards regression model to estimate the age- and multivariable-adjusted hazard ratios (HRs) for the association between vaginal estrogen use (current users vs nonusers) and various clinical end points. The Cox proportional hazards regression models included age in years as the time scale, stratified by calendar time in 2-year intervals, and allowed for the possible interaction between calendar time and age in the baseline hazards to be accounted for nonparametrically. Covariates included in the multivariable adjusted models were selected based on apparent differences in study characteristics between users and nonusers of

vaginal estrogen and a prior knowledge of variables that could confound the association between hormone therapy use and chronic disease risk. In multivariable adjusted model 1, we adjusted for race, smoking status, alcohol intake, physical activity, body mass index (BMI), aspirin use, age at menopause, bilateral oophorectomy status (except for ovarian cancer models), and past systemic hormone therapy use. Models with cardiovascular end-points and mortality end-points additionally adjusted for aspirin use. In multivariable adjusted model 2, we further adjusted for parental history of cancer. Models with cardiovascular events and mortality as the endpoint additionally adjusted for history of chronic disease including a history of type 2 diabetes, hypertension, hypercholesterolemia, and parental history of MI before the age of 60 years. Models with breast cancer as an outcome additionally adjusted model 2 for height, parity, age at first birth, BMI at age 18, and history of benign breast disease. Because women who had mammogram screening in the previous cycle were more likely to be diagnosed with invasive breast cancer,⁴⁴ we also adjusted for this surveillance-related variable. To fully and completely account for any effect of systemic hormone therapy use on risk of invasive breast cancer, in sensitivity analyses for breast cancer models, we further excluded past systemic hormone therapy users at study enrollment and follow-up. For endometrial cancer models, we conducted two additional sensitivity analyses. First, because NHS women during early follow-up were more likely to use vaginal estrogen with much higher doses, we conducted a sensitivity analysis based on starting follow-up in 1992 (instead of 1982). Second, because systemic progestin is prescribed to protect the endometrium, in sensitivity analyses, for endometrial cancer models, we only censored women upon starting systemic estrogen therapy and we adjusted for past use of systemic estrogen plus progestin therapy and systemic progestin therapy. Because the risks associated with hormone therapy (estrogen alone or with progestin) differ by hysterectomy status, results for all outcomes are also presented by hysterectomy status (time-varying) in sensitivity analyses. All statistical tests were two sided and were conducted using SAS for UNIX (version 9.3, SAS Institute Inc, Cary, NC).

RESULTS

Characteristics of participants at entry into analysis

In the overall analytic sample, users of vaginal estrogen had an overall favorable risk profile (Table 1). Compared to nonusers, vaginal estrogen users were more likely to be never smokers, had a lower BMI, a marginally higher level of physical activity, and a lower prevalence of hypertension. However, these women were more likely to have had a bilateral oophorectomy, a hysterectomy, and a history of benign breast disease. They were also more likely to have a family history of cancer. Women using vaginal estrogen were more likely to be younger at first birth, more likely to have two or more children, and more likely to be past users of systemic hormone therapy. There were no appreciable

TABLE 1. Characteristics of participants at entry into analysis by vaginal estrogen use in postmenopausal women

Characteristic ^a	Overall	
	No VE use	VE use
N	52,901	896
Age ^b , y	54.4 (3.9)	54.8 (4.0)
White, %	97	98
Age at menopause, y	49.6 (4.4)	49.0 (4.8)
Age at first birth, y	25.5 (12.4)	24.1 (12.6)
Body mass index, kg/m ²	25.9 (5.2)	24.2 (4.1)
Height, inches	64.3 (3.3)	64.3 (2.3)
Smoking ^c		
Never, %	43	49
Past, %	31	36
Current, %	27	15
Physical activity, MET-h/wk	14.9 (21.3)	15.2 (17.4)
Alcohol intake, g/d	6.3 (10.8)	6.5 (9.7)
Bilateral oophorectomy, %	11	16
Hysterectomy, %	22	32
Parity ^c		
Nulliparous, %	6	10
1 Child, %	7	6
2-3 Children, %	52	57
>3 Children, %	36	27
History of past systemic hormone therapy use, %	19	47
Hypertension, %	33	28
Hypercholesterolemia, %	23	24
History of diabetes, %	12	11
History of benign breast disease, %	34	45
Parental history of early MI, %	14	14
Family history of cancer, %	19	21
Aspirin use ^d , %	15	16

MET, metabolic equivalent task; MI, myocardial infarction; VE, vaginal estrogen.

^aValues are means (SD) or percentages and are standardized to the age distribution of the study population.

^bNot age adjusted.

^cValues for polytomous variables do not add up to a 100 due to rounding.

^dAt least 1 tablet per day.

differences in age at study entry, race, height, history of diabetes, parental history of MI, or aspirin use between users and nonusers of vaginal estrogen. The average duration of vaginal estrogen use, over follow-up, was 35.7 months.

Risk for major health outcomes

In the overall sample, in the age adjusted model, compared to nonusers, users of vaginal estrogen had a lower risk of total MI (HR 0.56, 95% confidence interval [CI] 0.36-0.87) and a marginally but nonsignificant lower risk of total stroke (HR 0.71, 95% CI 0.47-1.09) (Table 2). There were no significant differences in the age-adjusted risk of pulmonary embolism/deep vein thrombosis, total invasive cancer, invasive breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, or hip fracture between users and nonusers of vaginal estrogen. In the fully adjusted model, after accounting for differences in race, smoking status, alcohol intake, physical activity, BMI, aspirin use, age at menopause, bilateral oophorectomy, past systemic hormone therapy use, history of hypertension, hypercholesterolemia, type 2 diabetes, parental history of early MI, and family history of cancer, we found no statistically significant difference between users and nonusers of vaginal estrogen in the risk of all major cardiovascular outcomes (including total MI, stroke, pulmonary embolism/deep vein thrombosis), cancer outcomes (including total invasive cancer, ovarian cancer, endometrial cancer, and colorectal cancer), or hip fracture. When we further adjusted breast cancer models for additional covariates such as height, parity, age at first birth, BMI at age 18, history of benign breast disease, and mammogram screening in the previous cycle, results remained null and nonsignificant (HR 1.07, 95% CI 0.78-1.47). When we further excluded past systemic hormone therapy users at entry and follow-up, the HR for invasive breast cancer among vaginal estrogen users remained unchanged (HR 1.07, 95% CI 0.77-1.47).

In sensitivity analyses, for endometrial cancer, when we started follow-up in 1992 (instead of 1982), results remained null and nonsignificant (HR = 1.52, 95% CI 0.78-2.98). In additional analyses, when we only censored women for past systemic estrogen use and adjusted for past systemic estrogen plus progestin or progestin alone use, the HR for endometrial cancer among VE users was attenuated and remained

TABLE 2. Hazard ratio and 95% confidence interval for health outcomes among postmenopausal users by vaginal estrogen use, 1982-2012

Outcome	No VE		VE		Age-adjusted model	Multivariable adjusted model 1 ^a	Multivariable adjusted model 2 ^b
	Cases	Person years	Cases	Person years			
Total MI	1,339	696,454	20	17,884	0.56 (0.36-0.87)	0.71 (0.45-1.10)	0.73 (0.47-1.13)
Stroke	1,188	699,023	22	17,972	0.71 (0.47-1.09)	0.82 (0.54-1.25)	0.85 (0.56-1.29)
PE/DVT	524	648,536	11	16,502	0.88 (0.48-1.60)	1.05 (0.58-1.92)	1.06 (0.58-1.93)
All cancer types	5,444	670,766	139	17,534	0.97 (0.82-1.15)	1.05 (0.89-1.25)	1.05 (0.89-1.25)
Invasive breast cancer	1,570	510,880	40	11,826	1.06 (0.77-1.44)	1.13 (0.82-1.55)	1.07 (0.78-1.47)
Ovarian cancer ^c	202	621,565	6	15,798	1.12 (0.50-2.54)	1.17 (0.52-2.66)	1.17 (0.52-2.65)
Endometrial cancer ^d	344	540,085	11	13,166	1.30 (0.71-2.38)	1.62 (0.88-2.97)	1.62 (0.88-2.97)
Colorectal cancer	649	711,936	13	18,199	0.73 (0.42-1.27)	0.78 (0.45-1.35)	0.77 (0.45-1.34)
Hip fracture	1,055	708,827	23	18,148	0.88 (0.58-1.33)	0.88 (0.58-1.34)	0.91 (0.60-1.38)

MI, myocardial infarction; PE/DVT, pulmonary embolism/deep vein thrombosis; VE, vaginal estrogen.

^aModel 1 was adjusted for age (y), calendar time, race, smoking status, alcohol intake, physical activity (MET-h/wk), body mass index (BMI; kg/m²), age at menopause, hysterectomy (except for endometrial cancer), bilateral oophorectomy (except for ovarian cancer), and history of past systemic hormone therapy use (y/n). Cardiovascular outcomes were also adjusted for aspirin use (at least 1/day).

^bModel 2 was adjusted for variables in model 1 and parental history of cancer. Cardiovascular models were also adjusted for history of high blood pressure, hypercholesterolemia, history of diabetes, and parental history of early MI. Breast cancer models were also adjusted for height, parity, age at first birth, BMI at age 18, history of benign breast disease, and mammogram screening in the previous cycle.

^cExcluded women with bilateral oophorectomy.

^dEndometrial cancer results are only shown for women with an intact uterus.

nonsignificant (HR = 1.24, 95% CI 0.64-2.41). When we examined the association between vaginal estrogen use and health outcomes by hysterectomy status, results remained similar to the overall sample with no differences in risk for cardiovascular and cancer outcomes (Fig. 1).

DISCUSSION

In this large prospective study of postmenopausal nurses, over a period of 18 years of follow-up, after accounting for differences in major confounders, we found that users and nonusers of vaginal estrogen did not have different risks for major cardiovascular outcomes (including total MI, stroke, pulmonary embolism/deep vein thrombosis), cancer outcomes (total invasive cancer, invasive breast, ovarian, endometrial, or colorectal cancer), or hip fracture. When we examined associations by hysterectomy status, results remained similar to the overall cohort.

Only a few previous studies have examined the association between vaginal estrogen use and various health outcomes, and only one previous study comprehensively examined the balance of risks and benefits associated with vaginal estrogen use.²⁷ Although use of oral conjugated equine estrogens (0.625 mg/d) was associated with an increased risk of stroke and deep vein thrombosis in the intervention phase of the Women's Health Initiative (WHI) Hormone Therapy (HT) trials,⁴⁵ we found no evidence for a higher risk for either of these outcomes with use of vaginal estrogen. Our findings for stroke are consistent with WHI Observational Study (WHI-OS) findings²⁷ that found no association with vaginal estrogen use. However, two studies from Scandinavian nations found a lower risk of stroke with vaginal estrogen use. A Danish national cohort of 980,003 postmenopausal women, aged 51 to 70 years,²⁹ documented a 35% (relative risk [RR] = 0.65, 95% CI 0.59-0.70) lower risk of stroke among vaginal estrogen users while a pooled analysis of five Swedish cohort studies³⁰ found that late initiation (>5 years since menopause onset) of vaginal HT was associated with a longer stroke-free period. The apparent discrepancies in these findings may be attributed to differences in study populations, more comprehensive adjustment for potential confounding variables in our study, and the types of vaginal hormones used. For example, while the Swedish analysis examined associations with vaginal HT which could include progestin creams, it remains unclear if the inverse association persisted when limited to vaginal estrogen use. For total MI, similar to the WHI-OS analysis (which examined coronary heart disease as an outcome),²⁷ we found an inverse association, albeit nonsignificant, with vaginal estrogen use.

For breast cancer, similar to the results of the WHI-OS analysis²⁷ and a study of postmenopausal women from Finland,⁴⁶ we found no association between vaginal estrogen use and incident breast cancer. Moreover, because use of systematic unopposed estrogen was not associated with an increased risk of breast cancer in either the intervention or the cumulative follow-up phases of the WHI HT trials,⁴⁵ it is unlikely that use of a low-dose vaginal estrogen would have an effect on risk of breast cancer.

With respect to endometrial cancer, consistent with the findings of Crandall et al²⁷ we found no evidence for a difference in risk between users and nonusers of vaginal estrogen. However, contrary to our findings, a Danish national cohort study found that compared to never users, users of vaginal estrogen therapy had a nearly two-fold risk of endometrial cancer (RR = 1.96, 95% CI 1.77-2.17).²⁸ The potential reasons underlying these differing findings, as articulated in a recent editorial,⁴⁷ included potential confounding by concomitant use of systemic hormone therapy in the Danish cohort, as a substantial proportion of women were using unopposed systemic estrogen. In both the WHI-OS cohort and the current study, current users of systemic hormone therapy were excluded at baseline and women were censored at the start of systemic hormone therapy during follow-up. This analytic approach allowed us to minimize any "effects" of unopposed systemic hormone therapy use on the endometrium. We also adjusted for the past systemic hormone therapy use. In sensitivity analyses, when we only censored who were current users of systemic estrogen therapy and adjusted for systemic estrogen plus progestin or systemic progestin therapy, results were attenuated and remained nonsignificant. Second, data from the National Danish Prescription Registry indicate that doses of vaginal estrogen in Denmark were generally higher (25 µg E2) than those in the United States (10 µg E2).⁴⁷ Because systemic absorption has been shown in women using vaginal E2 at doses of 25 µg,⁴⁸ the safety of estrogen on the endometrium at these higher doses remains unknown. At the same time, 10 µg vaginal E2 results in at least 50% lower mean E2 concentrations than with the 25 µg dose within 24 hours after dosing.²⁵ Because NHS women used vaginal estrogen therapy with much higher doses during early follow-up, when we initiated follow-up in 1992 instead of 1982, results for endometrial cancer were null and nonsignificant. A 2006 Cochrane review of four trials found that, when compared to a placebo, vaginal estrogen therapy was not associated with a statistically significant risk of endometrial hyperplasia among postmenopausal women, although no data were available to evaluate safety beyond 6 months of use.⁴⁹ However, our findings combined with those of the WHI-OS²⁷ provide reassurance that use of low-dose vaginal estrogen for more than 6 months is not associated with a higher risk of endometrial cancer. Still, because GSM symptoms could last for a long time thereby warranting a longer treatment duration, additional studies are needed to examine the safety of longer duration of use beyond what was observed in the WHI-OS and the NHS. Nonetheless, our conclusions are in line with recommendations by The North American Menopause Society and the American College of Obstetricians and Gynecologists that state that low-dose vaginal estrogen can be used indefinitely, if needed, and do not advise use of concomitant progestin to protect the endometrium.^{9,10}

Although systemic HT use has consistently been shown to be associated with a lower risk of hip fracture, we did not document such an association with vaginal estrogen use. In line with our results, a case-control study of 4,589




FIG. 1. Hazard ratio (HR) and 95% confidence interval (CI) for health outcomes among vaginal estrogen (VE) users overall and by hysterectomy status. VE and hysterectomy status were included in the model as time varying covariates. Analysis for ovarian cancer was not conducted on women with a bilateral oophorectomy. Ovarian cancer results are not presented by hysterectomy status due to model convergence issues. Endometrial cancer analysis was only conducted on women with an intact uterus. All models were adjusted for age, calendar time, race, smoking status, alcohol intake, physical activity, body mass index (BMI), age at menopause, hysterectomy status (for all overall models except endometrial cancer), bilateral oophorectomy (except for ovarian cancer), past systemic hormone therapy use, and parental history of cancer. In addition to these covariates, breast cancer models were also adjusted for height, parity, age at first birth, BMI at age 18, history of benign breast disease, and mammogram screening in the previous cycle. Cardiovascular endpoints were additionally adjusted for aspirin use, history of high blood pressure, hypercholesterolemia, history of type 2 diabetes, and parental history of early MI. CI, confidence interval; DVT, deep vein thrombosis; HR, hazard ratio; MI, myocardial infarction; NA, not applicable; NR, not reported.

postmenopausal women also found no association between low-potency vaginal estrogen and hip fracture risk (OR = 0.82, 95% CI 0.50-1.36).⁵⁰ However, the WHI-OS analysis documented a strong and inverse association between current vaginal estrogen use and hip fracture risk (RR = 0.40, 95% CI 0.19-0.85) although this estimate is based on only 10 cases of hip fracture in vaginal estrogen users.²⁷ In a small randomized controlled trial of 30 healthy women, aged 60 years or more, ultralow doses of parenteral E2 (7.5 µg/24 h) for 6 months increased forearm bone mineral density compared to nonusers,⁵¹ suggesting a potentially causal role for E2 in lowering fracture risk.

The findings of our study together with those of the WHI-OS provide substantial and consistent evidence for the safety of vaginal estrogen use in postmenopausal women in relation to multiple health outcomes. Despite lack of any observational or clinical trial evidence for chronic disease risks related to vaginal estrogen use, the FDA has issued a boxed warning on the package label for low-dose vaginal estrogen. This black-box warning, which is the highest level of warning information in labeling, is designed to call attention to serious or life-threatening risks. The specified risks which include endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia stem from the findings of the WHI HT trials¹⁹ that used systemic doses of hormone therapy and should not be extrapolated to the lower doses found in vaginal estrogen regimens. Unlike doses of estrogen therapy used to treat vasomotor symptoms, low-dose vaginal estrogen results in minimal systemic absorption and circulating E2 and estrone concentrations generally remain within the normal postmenopausal range.^{23,24,26}

It is worth mentioning that prevalence of vaginal estrogen use in our study (<3%) was much lower than what was observed in the WHI-OS (~10%). Although the reasons for the lower prevalence are not entirely clear, one possible reason is that women who reported using vaginal estrogen use in a questionnaire cycle and who also reported using a systemic form of hormone therapy were excluded from the analysis. Along with the low prevalence of vaginal estrogen use, the average duration of use (37.5 mo) was also low in our population. Given the long lasting duration of GSM symptoms, additional data on the safety of longer duration of use of vaginal estrogen is warranted.

The strengths of the current study include prospective collection of hormone therapy use and health outcomes, confirmation of clinical endpoints, high rates of follow-up, and our ability to examine the risk-benefit profile by hysterectomy status. Still, several limitations are worth mentioning. First, although we comprehensively adjusted for a number of covariates that could confound the association between vaginal estrogen use and health outcomes, residual confounding remains a possibility given the observational nature of the study. Second, we did not have information on the individual types of vaginal therapy formulations such as creams, rings, tablets, and suppositories, or the doses used. During early follow-up in the NHS, it is possible that some women were

using vaginal estrogen with much higher doses rather than the currently prescribed low-dose regimens. However, we did not have information to address this issue. Third, we did not have information on Femring, which contains systemic doses of estrogen vaginally. Still, Femring use is unlikely to affect results, because it was not approved until 2003 and is an uncommonly prescribed form of systemic HT. A small open-label, randomized, multiple-dose, two-treatment crossover study among 24 postmenopausal women showed that when women received 0.5 g Premarin vaginal cream (equivalent to 0.3 mg conjugated estrogens, 0.625 mg/g) for 7 days, unconjugated plasma E2 and estrone levels remained within the normal postmenopausal range.²⁴ Still the safety of these “higher” doses of vaginal estrogen need to be ascertained in future studies. Fourth, our study includes only health professionals mainly of European ancestry (~97%) with a high educational status. Although the lack of racial diversity limits our ability to generalize our findings to other ethnic groups, the consistency of these results with those of the WHI-OS supports the generalizability of our study. Furthermore, the high educational status can be perceived as an advantage because high-quality and reliable data can be collected from our study participants. Finally, given the observational nature of our study, we cannot establish cause and effect relationships.

CONCLUSIONS

In conclusion, our data lend support to the safety of vaginal estrogen use, because no excess risk of cardiovascular disease or cancer was observed among women who self-reported use of various delivery systems and doses of vaginal estrogen. Our findings provide a comprehensive summary of the relationship between vaginal estrogen and multiple health outcomes and offer reassurance regarding the safety of low-dose vaginal estrogen to treat GSM.

Acknowledgments: The authors would like to thank the participants and staff of the Nurses’ Health Study that contributed data for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

REFERENCES

1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. *Am Fam Physician* 2000;61:3090-3096.
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. *J Sex Med* 2009;6:2133-2142.
3. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. *Climacteric* 2016;19:188-197.
4. Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause: prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. *Climacteric* 2018;21:167-173.
5. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. *Maturitas* 2014;79:349-354.
6. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. *Menopause* 2013;20:888-902.

7. DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. *J Womens Health (Larchmt)* 2015;24:713-722.
8. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. *Climacteric* 2014;17:3-9.
9. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol* 2014;123:202-216.
10. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause* 2017;24:728-753.
11. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2015;100:3975-4011.
12. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. *Obstet Gynecol* 2014;124:1147-1156.
13. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol* 1998;92 (4 pt 2):722-727.
14. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2016; CD001500.
15. Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. *JAMA Intern Med* 2018;178:681-690.
16. Pinkerton JV, Kaunitz AM, Manson JE. Not time to abandon use of local vaginal hormone therapies. *Menopause* 2018;25:855-858.
17. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. *J Sex Med* 2017;14:413-424.
18. Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. *Menopause* 2014;21:911-916.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-333.
20. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. *Menopause* 2010;17:194-203.
21. Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. *Clin Obstet Gynecol* 2015;58:476-491.
22. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. *Am J Obstet Gynecol* 2002;186:944-947.
23. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. *Climacteric* 2005;8:83-92.
24. Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. *Fertil Steril* 2010;94:2365-2368.
25. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. *Climacteric* 2010;13:219-227.
26. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. *Menopause* 2002;9:179-187.
27. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. *Menopause* 2018;25:11-20.
28. Mørch LS, Kjaer SK, Keiding N, Lokkegaard E, Lidegaard O. The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. *Int J Cancer* 2016;138:1506-1515.
29. Lokkegaard E, Nielsen LH, Keiding N. Risk of stroke with various types of menopausal hormone therapies: a national cohort study. *Stroke* 2017;48:2266-2269.
30. Carrasquilla GD, Frumento P, Berglund A, et al. Postmenopausal hormone therapy and risk of stroke: a pooled analysis of data from population-based cohort studies. *PLoS Med* 2017;14:e1002445.
31. Belanger C, Speizer FE, Hennekens CH, Rosner B, Willett W, Bain C. The nurses' health study: current findings. *Am J Nurs* 1980;80:1333.
32. Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses' health study. *Am J Nurs* 1978;78:1039-1040.
33. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6:49-62.
34. Bao Y, Bertolia ML, Lenart EB, et al. Origin, methods, and evolution of the three nurses' health studies. *Am J Public Health* 2016;106:1573-1581.
35. World Health Organization. Regional Office for Europe. Ischemic Heart Disease Registers: Report of the Fifth Working Group (including a Second Revision of the Operating Protocol), Convened by the Regional Office for Europe of the World Health Organization; Copenhagen, 26-29 April 1971. [Fifth Working Group on Ischaemic Heart Disease Registers]; 1971. Available at: <https://books.google.com/books?id=frb3MwEA-CAAJ>.
36. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000;36:959-969.
37. Walker AE, Robins M, Weinfeld FD. The national survey of stroke. Clinical findings. *Stroke* 1981;12 (2 pt 2, suppl 1):113-144.
38. Pun VC, Hart JE, Kabrhel C, Camargo CA Jr, Baccarelli AA, Laden F. Prospective study of ambient particulate matter exposure and risk of pulmonary embolism in the nurses' health study cohort. *Environ Health Perspect* 2015;123:1265-1270.
39. Kabrhel C, Varraso R, Goldhaber SZ, Rimm E, Camargo CA Jr. Physical inactivity and idiopathic pulmonary embolism in women: prospective study. *BMJ* 2011;343:d3867.
40. Poole EM, Lin WT, Kvaskoff M, De Vivo I, Terry KL, Missmer SA. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. *Cancer Causes Control* 2017;28:437-445.
41. Puckett CD. The Educational Annotation of ICD-9-CM; Diseases and Procedures Tabular Lists. Reno, NV: Channel Publishing, Ltd.; 1986.
42. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the national death index and equifax nationwide death search. *Am J Epidemiol* 1994; 140:1016-1019.
43. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the national death index. *Am J Epidemiol* 1984;119:837-839.
44. Zahl PH, Jørgensen KJ, Maehlen J, Gotzsche PC. Biases in estimates of over-detection due to mammography screening. *Lancet Oncol* 2008;9:199-201author reply 2.
45. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013;310:1353-1368.
46. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. *Obstet Gynecol* 2006;108: 1354-1360.
47. Pinkerton JV, Kaunitz AM, Manson JE. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. *Menopause* 2017;24:1329-1332.
48. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. *Menopause* 2009;16:30-36.
49. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2006;CD001500.
50. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Use of low potency estrogens does not reduce the risk of hip fracture. *Bone* 2002;30:613-618.
51. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. *Am J Obstet Gynecol* 1997;177:115-119.